跳至主要内容
临床试验/NCT01608789
NCT01608789已完成不适用

Virtue® Male Sling European Study

Coloplast A/S26 个研究点 分布在 8 个国家目标入组 123 人开始时间: 2012年8月27日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Coloplast A/S
入组人数
123
试验地点
26
主要终点
Improvement of urinary incontinence based on 24-hour pad test

研究概览

简要总结

This study is a prospective, single arm, non-randomized, multi-center clinical study that will be conducted in Europe. It is designed to assess efficacy and safety of the Virtue® Male Sling in post-prostatectomy urinary incontinence.

详细描述

This study is a prospective, single arm, non-randomized, multi-center clinical study that will be conducted at up to thirteen centers in Europe. It is designed to assess efficacy and safety of the Virtue® Male Sling. One hundred and twenty-one subjects, satisfying criteria for selection, will be implanted with no more than 15 implanted per site. The study's primary end point will be evaluated at 12 months with continued data collection through 36 months.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • The subject has an estimated life expectancy of more than 5 years
  • The subject has confirmed stress urinary incontinence (SUI) through medical history, urodynamics, and/or physical exam for at least 6 months
  • The subject has intrinsic sphincter deficiency due to radical prostatectomy completed at least 1 year prior to implantation date
  • The subject has a good bladder function
  • The subject has failed non-invasive therapies, eg. Pelvic Floor/Kegel exercises, behavioral modification, or biofeedback, for at least 6 months
  • The subject is willing to have the Virtue® Male Sling implanted
  • The subject is able and willing to complete all follow-up visits and procedures indicated in this protocol

排除标准

  • The subject is unable or unwilling to comply with all follow-up requirements according to the study protocol
  • The subject has an active urinary tract infection or active skin infection in region of surgery (temporary exclusion)
  • The subject has compromised immune systems or any other conditions that affect healing
  • The subject has serious bleeding disorders
  • The subject has an urinary incontinence that is not mainly a stress urinary incontinence
  • The subject has a stress urinary incontinence due to TransUrethral Resection or laser surgery of the Prostate (TURP)
  • The subject has incontinence due to neurogenic causes defined as multiple sclerosis, spinal cord/brain injury, CVA, detrusor-external sphincter dyssynergia, Parkinson's disease, or similar conditions
  • The subject had a previous implant (male sling, Artificial Urinary Sphincter) to treat stress urinary incontinence (previous implanted bulking agents are allowed)
  • The subject has undergone radiation, cryosurgery, or brachy therapy to treat prostate or other pelvic cancer within 6 months
  • The subject is likely to undergo radiation therapy within the next 3 months
  • The subject has a postvoid residual (PVR) > or = 150mL
  • The subject has recently required transurethral instrumentation for urethral or urethro-vesical anatomosis stricture within the previous 6 months
  • The subject is enrolled in a concurrent clinical study of any treatment (drug or device) that could affect continence function without the sponsors' approval
  • The subject is deemed unfit for male sling implantation or participation in a research protocol as determined by the attending physician

结局指标

主要结局

Improvement of urinary incontinence based on 24-hour pad test

时间窗: 1 year

The primary effectiveness end point will be improvement in pad weight defined as at least a 50% reduction in 24-hour pad weight from baseline to 12-months.

Safety of the device characterized by reported adverse events

时间窗: 1 year

Safety of the device, including the implant procedure.

次要结局

  • Assessment of the frequency, severity and impact on quality of life of urinary incontinence based on ICIQ-UI short form(baseline, 1 months, 3 months, 6 months, 1 year, 2 years and 3 years)
  • Safety of the device characterized by reported adverse events(Intraoperative, 1 month, 3 months, 6 months, 2 years, 3 years)
  • Improvement of urinary incontinence based on 24-hour pad test(Baseline, 1 month, 3 months, 6 months, 2 years, 3 years)
  • Improvement of urinary incontinence based on number of pad used(baseline,1 month, 3 months, 6 months, 1 year, 2 years and 3 years)
  • Improvement of urinary incontinence based on PGI-I(1 month, 3 months, 6 months, 1 year, 2 years, 3 years)
  • Patient satisfaction questionaire(1 month, 3 months, 6 months, 1 year, 2 years, 3 years)

研究者

发起方
Coloplast A/S
申办方类型
Industry
责任方
Sponsor

研究点 (26)

Loading locations...

相似试验

Virtue® European Study | 临床试验